Entera Bio Ltd Cash Flow Conversion Efficiency
Entera Bio Ltd cash flow conversion efficiency. Based on the latest financial reports, Entera Bio Ltd (ENTX) has a cash flow conversion efficiency ratio of -0.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.46 Million) by net assets ($7.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Entera Bio Ltd (2015–2025)
Cash flow conversion efficiency of Entera Bio Ltd from 2015 to 2025. This chart illustrates how Entera Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Entera Bio Ltd share price for real-time trading data and today's change.
Entera Bio Ltd Cash Flow Conversion Ratio Explained
Entera Bio Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Entera Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entera Bio Ltd ranked by their cash flow conversion efficiency. Also see ENTX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EUROSEAS LTD DL -01
F:2LE1
|
0.078x |
|
Andes Technology Corp
TW:6533
|
-0.006x |
|
Universal Logistics Holdings Inc
NASDAQ:ULH
|
0.045x |
|
Csd Water Service Co Ltd
SHG:603903
|
0.110x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.018x |
|
Hangzhou CNCR-IT Co Ltd
SHE:300250
|
0.017x |
|
Zhejiang Risun Intelligent Technology Co. Ltd. A
SHG:688215
|
N/A |
|
Delek Automotive Systems Ltd
TA:DLEA
|
0.164x |
Annual Cash Flow Conversion Efficiency for Entera Bio Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Entera Bio Ltd from 2015 to 2025. Review ENTX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.10 Million | $-7.37 Million | -0.563x | +33.33% |
| 2024-12-31 | $8.08 Million | $-6.82 Million | -0.844x | -19.89% |
| 2023-12-31 | $10.39 Million | $-7.31 Million | -0.704x | +33.81% |
| 2022-12-31 | $11.75 Million | $-12.50 Million | -1.063x | -164.76% |
| 2021-12-31 | $22.57 Million | $-9.06 Million | -0.402x | +71.43% |
| 2020-12-31 | $7.51 Million | $-10.56 Million | -1.406x | -87.86% |
| 2019-12-31 | $11.92 Million | $-8.92 Million | -0.748x | +22.73% |
| 2018-12-31 | $10.12 Million | $-9.80 Million | -0.968x | -775.20% |
| 2017-12-31 | $-31.56 Million | $-4.53 Million | 0.143x | +15.24% |
| 2016-12-31 | $-25.25 Million | $-3.14 Million | 0.124x | -8.53% |
| 2015-12-31 | $-25.69 Million | $-3.50 Million | 0.136x | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more